The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Intercept Pharmaceuticals Inc

Nasdaq: ICPT
Last

(U.S.) $110.14

Today's change-4.53 -3.95%
Updated January 20 4:00 PM EST. Delayed by at least 15 minutes.
 

Intercept Pharmaceuticals Inc

Nasdaq: ICPT
Last

(U.S.) $110.14

Today's change-4.53 -3.95%
Updated January 20 4:00 PM EST. Delayed by at least 15 minutes.

Intercept Pharmaceuticals Inc down (U.S.)$4.53

Intercept Pharmaceuticals Inc closed sharply lower Friday, dropping (U.S.)$4.53 or 3.95% to (U.S.)$110.14. Over the last five days, shares have lost 3.70% and 8.30% over the last 52 weeks. This security has underperformed the S&P 500 by 30.46% during the last year.

Key company metrics

  • Open(U.S.) $112.22
  • Previous close(U.S.) $114.67
  • High(U.S.) $113.84
  • Low(U.S.) $108.62
  • Bid / Ask(U.S.) $105.00 / (U.S.) $111.30
  • YTD % change+1.37%
  • Volume509,539
  • Average volume (10-day)538,359
  • Average volume (1-month)513,908
  • Average volume (3-month)484,561
  • 52-week range(U.S.) $89.76 to (U.S.) $177.93
  • Beta-2.08
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$15.53
Updated January 20 4:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-3,288.25%

Intercept Pharmaceuticals Inc has a net profit margin of -3,288.25%. Besides being negative, it is also below the industry average and implies that this company is not effective at turning revenues into bottom line profit.
Company Books

S&P TSX0.90%Sector:HealthcareIndustry:Biotechnology

Latest Company News

  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2016Q2/2016Q1/2016Q4/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201609/30/2016Jun 30, 201606/30/2016Mar 31, 201603/31/2016Dec 31, 201512/31/2015
Revenue5600
Total other revenue--------
Total revenue5600
Gross profit--------
Total cost of revenue--------
Total operating expense888412889
Selling / general / administrative44429045
Research & development44413744
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-83-78-127-89
Interest income (expense), net non-operating-7------
Gain (loss) on sale of assets--------
Other--------
Income before tax-89-77-127-88
Income after tax-89-77-127-88
Income tax, total--------
Net income-89-77-127-88
Total adjustments to net income--------
Net income before extra. items-89-77-127-88
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-89-77-127-88
Inc. avail. to common incl. extra. items-89-77-127-88
Diluted net income-89-77-127-88
Dilution adjustment--------
Diluted weighted average shares25252424
Diluted EPS excluding extraordinary itemsvalue per share-3.59-3.14-5.17-3.62
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share-3.59-3.14-5.17-3.62